"To trade at $40 would mean RAC market cap of ~$20 Billion.....or 1/6th value of CSL which is a Biotech gorilla. Is that realistic?"
You stuffed up the maths, $40 would give us a market cap of ~$5.5B. Very justifiable given our pipeline and looking at international peers and past m&a transactions.
You're also underestimating the competitiveness in the oncology m&a space at the moment. There have been many ph III flops recently which will just increase competition further. I'm not saying that we can get competing offers from where we currently are ($3.70) that'll drive us to the $85 mark but I also don't believe we need to be close to $40 either. Just my opinion.
Ann: Race Strategic Update March 2021, page-226
-
- There are more pages in this discussion • 294 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
-0.045(3.01%) |
Mkt cap ! $247.1M | |||
| Open | High | Low | Value | Volume |
| $1.50 | $1.52 | $1.45 | $62.74K | 42.47K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 14110 | $1.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.49 | 666 | 1 |
View Market Depth
| Last trade - 16.10pm 28/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |